267 related articles for article (PubMed ID: 26630531)
1. Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.
Maillet D; Gan HK; Blay JY; You B; Péron J
Eur J Cancer; 2016 Jan; 52():26-32. PubMed ID: 26630531
[TBL] [Abstract][Full Text] [Related]
2. The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members.
Maillet D; Blay JY; You B; Rachdi A; Gan HK; Péron J
Ann Oncol; 2016 Jan; 27(1):192-8. PubMed ID: 26483049
[TBL] [Abstract][Full Text] [Related]
3. Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review.
Péron J; Maillet D; Gan HK; Chen EX; You B
J Clin Oncol; 2013 Nov; 31(31):3957-63. PubMed ID: 24062406
[TBL] [Abstract][Full Text] [Related]
4. Analysis and reporting of adverse events in randomised controlled trials: a review.
Phillips R; Hazell L; Sauzet O; Cornelius V
BMJ Open; 2019 Mar; 9(2):e024537. PubMed ID: 30826796
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for the Reporting of Harms in Manuscripts on Clinical Trials Assessing Osteoarthritis Drugs: A Consensus Statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).
Honvo G; Bannuru RR; Bruyère O; Rannou F; Herrero-Beaumont G; Uebelhart D; Cooper C; Arden N; Conaghan PG; Reginster JY; Thomas T; McAlindon T
Drugs Aging; 2019 Apr; 36(Suppl 1):145-159. PubMed ID: 31073927
[TBL] [Abstract][Full Text] [Related]
6. Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials.
Basch E; Rogak LJ; Dueck AC
Clin Ther; 2016 Apr; 38(4):821-30. PubMed ID: 27045992
[TBL] [Abstract][Full Text] [Related]
7. Improving attribution of adverse events in oncology clinical trials.
George GC; Barata PC; Campbell A; Chen A; Cortes JE; Hyman DM; Jones L; Karagiannis T; Klaar S; Le-Rademacher JG; LoRusso P; Mandrekar SJ; Merino DM; Minasian LM; Mitchell SA; Montez S; O'Connor DJ; Pettit S; Silk E; Sloan JA; Stewart M; Takimoto CH; Wong GY; Yap TA; Cleeland CS; Hong DS
Cancer Treat Rev; 2019 Jun; 76():33-40. PubMed ID: 31108240
[TBL] [Abstract][Full Text] [Related]
8. Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials.
Cornelius V; Cro S; Phillips R
Trials; 2020 Dec; 21(1):1028. PubMed ID: 33353566
[TBL] [Abstract][Full Text] [Related]
9. Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review.
Komorowski AS; MacKay HJ; Pezo RC
Cancer Med; 2020 Jul; 9(14):5035-5050. PubMed ID: 32452660
[TBL] [Abstract][Full Text] [Related]
10. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
[TBL] [Abstract][Full Text] [Related]
11. Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: an empirical assessment.
Hammad TA; Neyarapally GA; Pinheiro SP; Iyasu S; Rochester G; Dal Pan G
Clin Trials; 2013; 10(3):389-97. PubMed ID: 23508987
[TBL] [Abstract][Full Text] [Related]
12. Acute and Late Adverse Events Associated With Radical Radiation Therapy Prostate Cancer Treatment: A Systematic Review of Clinician and Patient Toxicity Reporting in Randomized Controlled Trials.
Holch P; Henry AM; Davidson S; Gilbert A; Routledge J; Shearsmith L; Franks K; Ingleson E; Albutt A; Velikova G
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):495-510. PubMed ID: 28126299
[TBL] [Abstract][Full Text] [Related]
13. Adverse event assessment, analysis, and reporting in recent published analgesic clinical trials: ACTTION systematic review and recommendations.
Smith SM; Wang AT; Katz NP; McDermott MP; Burke LB; Coplan P; Gilron I; Hertz SH; Lin AH; Rappaport BA; Rowbotham MC; Sampaio C; Sweeney M; Turk DC; Dworkin RH
Pain; 2013 Jul; 154(7):997-1008. PubMed ID: 23602344
[TBL] [Abstract][Full Text] [Related]
14. Information on adverse events in randomised clinical trials assessing drug interventions published in four medical journals with high impact factors.
Maggi CB; Griebeler IH; Dal Pizzol Tda S
Int J Risk Saf Med; 2014; 26(1):9-22. PubMed ID: 24796347
[TBL] [Abstract][Full Text] [Related]
15. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines.
Mistry P; Dunn JA; Marshall A
BMC Med Res Methodol; 2017 Jul; 17(1):108. PubMed ID: 28720094
[TBL] [Abstract][Full Text] [Related]
16. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
Drilon A; Eaton AA; Schindler K; Gounder MM; Spriggs DR; Harris P; Ivy SP; Iasonos A; Lacouture ME; Hyman DM
Cancer; 2016 Apr; 122(8):1228-37. PubMed ID: 26916138
[TBL] [Abstract][Full Text] [Related]
17. Identification, collection, and reporting of harms among non-industry-sponsored randomized clinical trials of pharmacologic interventions in the critically ill population: a systematic review.
Moskowitz A; Andersen LW; Holmberg MJ; Grossestreuer AV; Berg KM; Granfeldt A
Crit Care; 2020 Jul; 24(1):398. PubMed ID: 32641148
[TBL] [Abstract][Full Text] [Related]
18. Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative.
Reeve BB; McFatrich M; Pinheiro LC; Weaver MS; Sung L; Withycombe JS; Baker JN; Mack JW; Waldron MK; Gibson D; Tomlinson D; Freyer DR; Mowbray C; Jacobs S; Palma D; Martens CE; Gold SH; Jackson KD; Hinds PS
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27650708
[TBL] [Abstract][Full Text] [Related]
19. Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance.
Aagaard L; Hallgreen CE; Hansen EH
Int J Obes (Lond); 2016 Nov; 40(11):1742-1747. PubMed ID: 27478924
[TBL] [Abstract][Full Text] [Related]
20. Survival end point reporting in randomized cancer clinical trials: a review of major journals.
Mathoulin-Pelissier S; Gourgou-Bourgade S; Bonnetain F; Kramar A
J Clin Oncol; 2008 Aug; 26(22):3721-6. PubMed ID: 18669458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
